AnteoTech (ASX:ADO) used its half-year update and investor Q&A to outline a reset of its cost base, a more targeted commercialization strategy, and progress across its battery and life sciences businesses, with management emphasizing that sales conversion and strategic partnerships are now the company’s primary focus.
Cost reset and funding runway
Management said the company has “reset” its cost base and streamlined operations to align with shareholder expectations around converting sales opportunities and building partnerships. In comparing the current half-year with the prior period, the company highlighted efforts to reduce operating costs and focus resources on what it called critical activities.
On revenue, management noted that revenue timing related to the Serum Institute affected the half-year result. The company said it received an order but did not dispatch it during the period and therefore could not recognize revenue, adding that Serum Institute revenues are typically recognized roughly every six months.
Commercialization process and sales execution
Management walked investors through its structured sales process and pointed to “evaluation and feedback” as a key stage where much of the half-year’s work was concentrated, alongside sales negotiations. It acknowledged shareholder questions about pace and said the company is working to improve communication and be more targeted in customer engagement.
In Q&A, management said it is tracking sales at a granular level and increasing use of its CRM system, which it tied to the addition of two professional salespeople. It said teams have targets, budgets, forecasts, and personal KPIs with a significant proportion tied to sales. It also described an internal initiative to “celebrate” and document sales wins to reinforce the end-to-end process.
The company also said it is working toward a new website, with one of the new sales hires tasked with sourcing quotes. Management indicated timing targeted by the end of the financial year, emphasizing it wants the site to be “fit for purpose” rather than a minor refresh.
Battery segment: samples, partnerships, and targeted markets
In batteries, management described a pipeline built over the last six months spanning its Anteo X, Anteo S, a joint product with Black Diamond Structures (BDS) referred to as “Simrax” (a beta test name), and its Ultranode anode technology.
- Black Diamond Structures / Simrax: Management said BDS has identified six potential customers and, because BDS is US-based, it can manage logistics for sending samples. The company said it planned to get the first beta samples out “by the end of this week” and that updates would be shared via social media.
- Anteo S separators: Management said it is seeing market demand for ceramic-coated separators, noting Anteo S remains in trial stage with multiple customers. It said it expected to gather feedback in South Korea.
- South Korea customer engagement: Management said it would be in South Korea the following week for the InterBattery conference alongside distributor Kangshin, meeting potential customers who have received samples and begun testing. It also said it requested Austrade support to reach customers outside Kangshin’s distributorship.
- US focus and conferences: Management described the US as a key jurisdiction, particularly for drone-related opportunities, and said it was preparing for a major industry conference at the end of March with product communications and meeting plans.
On Ultranode, management said development is continuing and highlighted discussions with two battery manufacturers focused on using Ultranode as a next-generation anode for drones. It said it is targeting manufacturers that already have production capability or facilities coming online, aiming to secure positions in new products.
Management also discussed the need to communicate how Ultranode competes against alternatives, including the supply chain and lowest-cost production advantages it believes micro-silicon offers relative to more complex options. It emphasized the importance of being specific about end-use value propositions such as performance, cost reduction, and ease of use.
Wyon update: progress described as slow
Addressing repeated investor questions about Wyon and the pace of progress, management said the relationship is supported by a dedicated team with fortnightly update meetings and a structured testing program. It characterized progress as “frustratingly slow” but “going well,” and said results are run and released by Wyon, leaving AnteoTech dependent on incoming data before it can disclose outcomes publicly.
Management added that the experience underscored the need to broaden the testing funnel beyond Wyon, with more parties evaluating Ultranode variants (Ultranode 70, 95, or Ultranode X) in end applications. It also noted that cells are now being assembled in Wyon’s miniature cell design, describing this as a step forward from coin-cell work.
Life sciences: expanding use cases and ongoing Serum Institute relationship
In life sciences, management said the business has been “incredibly busy” and pointed to ongoing engagement with the Serum Institute. It said the head of the unit recently met the Serum Institute in India and provided prototypes of new products, with the relationship being maintained as strongly as possible.
Management also described work to broaden where its AnteoBind technology can be used in diagnostics. While lateral flow and Luminex have been historical focus areas, the company highlighted additional work in chemiluminescence and ELISA plates. It said it has been preparing a comparison paper on AnteoBind’s chemiluminescence performance and indicated it had made “very good progress” toward publishing it in the near future.
It also flagged “next generation” potential in biosensors, referencing its involvement in the MOBIUS research group and describing future applications such as wearable sensors communicating with smartphones.
In closing remarks, management reiterated that it believes the company is positioned to move forward after streamlining operations and putting “people, processes, plans and opportunities” in place. It said the key to improving market confidence and, by extension, the share price is delivering tangible progress and sustaining news flow, while noting that some customers are large and may have their own timing constraints, including fundraising.
About AnteoTech (ASX:ADO)
AnteoTech Limited develops, commercializes, manufactures, and distributes products for clean energy technology and life science markets primarily in Australia, Asia, Europe, and North America. Its products include AnteoBind ready-to-use applications to streamline and enhance the conjugation process; and AnteoX, an additive that reinforces battery binders helping maximize performance of silicon containing anodes. The company was formerly known as Anteo Diagnostics Limited and changed its name to AnteoTech Limited in November 2019.
